These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16173263)

  • 1. Successful treatment of resistant Behçet's disease with etanercept.
    Atzeni F; Sarzi-Puttini P; Capsoni F; Mecchia M; Marrazza MG; Carrabba M
    Clin Exp Rheumatol; 2005; 23(5):729. PubMed ID: 16173263
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of etanercept in the treatment of a patient with Behçet's disease.
    Curigliano V; Giovinale M; Fonnesu C; Cerquaglia C; Verrecchia E; Turco S; Manganelli C; Manna R
    Clin Rheumatol; 2008 Jul; 27(7):933-6. PubMed ID: 18330611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of mucocutaneous Behçet's disease responding to etanercept.
    Sommer A; Altmeyer P; Kreuter A
    J Am Acad Dermatol; 2005 Apr; 52(4):717-9. PubMed ID: 15793540
    [No Abstract]   [Full Text] [Related]  

  • 4. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.
    Alty JE; Monaghan TM; Bamford JM
    Clin Neurol Neurosurg; 2007 Apr; 109(3):279-81. PubMed ID: 17174468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behçet's syndrome: from aetiology to treatment.
    Powell RJ
    Adv Exp Med Biol; 2003; 528():481-6. PubMed ID: 12918749
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of recurrent oral aphthous ulcers with etanercept.
    Scheinberg MA
    Clin Exp Rheumatol; 2002; 20(5):733-4. PubMed ID: 12412213
    [No Abstract]   [Full Text] [Related]  

  • 7. Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders.
    Calamia KT
    Adv Exp Med Biol; 2003; 528():545-9. PubMed ID: 12918761
    [No Abstract]   [Full Text] [Related]  

  • 8. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
    van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
    Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches in the treatment of Adamantiades-Behçet's disease.
    Pipitone N; Olivieri I; Cantini F; Triolo G; Salvarani C
    Curr Opin Rheumatol; 2006 Jan; 18(1):3-9. PubMed ID: 16344613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.
    Melikoglu M; Fresko I; Mat C; Ozyazgan Y; Gogus F; Yurdakul S; Hamuryudan V; Yazici H
    J Rheumatol; 2005 Jan; 32(1):98-105. PubMed ID: 15630733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
    Sfikakis PP; Markomichelakis N; Alpsoy E; Assaad-Khalil S; Bodaghi B; Gul A; Ohno S; Pipitone N; Schirmer M; Stanford M; Wechsler B; Zouboulis C; Kaklamanis P; Yazici H
    Rheumatology (Oxford); 2007 May; 46(5):736-41. PubMed ID: 17403712
    [No Abstract]   [Full Text] [Related]  

  • 12. A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.
    Watanabe S; Aizawa-Yashiro T; Tsuruga K; Kinjo M; Ito E; Tanaka H
    Rheumatol Int; 2013 Dec; 33(12):3105-8. PubMed ID: 23266507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept in the treatment of intestinal Behcet's disease.
    Ma D; Zhang CJ; Wang RP; Wang L; Yang H
    Cell Biochem Biophys; 2014 Jul; 69(3):735-9. PubMed ID: 24622940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laryngeal involvement in Behcet's disease--a challenge for treatment.
    Gross M; Ben-Chetrit E
    Clin Rheumatol; 2013 Mar; 32 Suppl 1():S75-7. PubMed ID: 20532579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unusual case of Behçet's syndrome: triggered by typhoid vaccination?
    Molloy ES; Powell FC; Doran MF; Ryan JG; Mulligan NJ; McCarthy CJ; Keogan MT; McCarthy GM
    Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S71-4. PubMed ID: 15515791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [10th International Conference on Behçet Syndrome. Berlin, June 27-29, 2002].
    Weschler B
    Rev Med Interne; 2002 Oct; 23(10):808-9. PubMed ID: 12428481
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
    Benitah NR; Sobrin L; Papaliodis GN
    Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.
    Arida A; Fragiadaki K; Giavri E; Sfikakis PP
    Semin Arthritis Rheum; 2011 Aug; 41(1):61-70. PubMed ID: 21168186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model.
    Choi B; Hwang Y; Kwon HJ; Lee ES; Park KS; Bang D; Lee S; Sohn S
    J Dermatol Sci; 2008 Nov; 52(2):87-97. PubMed ID: 18585901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of necrobiosis lipoidica with etanercept and adalimumab.
    Zhang KS; Quan LT; Hsu S
    Dermatol Online J; 2009 Dec; 15(12):12. PubMed ID: 20040262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.